CJC-1295 (without DAC)
← All compounds

CJC-1295 (without DAC)

Well Researched

First effectsWeek 2-4
Full benefitsWeek 12+
Regulatory Limbo

CJC-1295 without DAC (also called Mod GRF 1-29) is a short-acting peptide that tells your pituitary gland to release more growth hormone. It works with your body's natural rhythm, triggering growth hormone in pulses rather than flooding your system with a constant supply. Because it clears quickly (about 30 minutes), you get a controlled boost without overwhelming the receptors that respond to the signal.

How it works

CJC-1295 attaches to growth hormone-releasing receptors in the pituitary gland, the small gland at the base of your brain that controls growth hormone output. This triggers a signaling chain inside those cells that causes them to release growth hormone in natural pulses, the same way your body does on its own. The short half-life means each dose produces a defined pulse rather than a prolonged elevation.

Key benefits

  • Stimulates growth hormone release while preserving your body's natural pulse pattern
  • Well-tolerated with minimal side effects at standard doses
  • Short duration reduces the risk of your receptors becoming less responsive over time
  • Allows precise control over the timing and size of growth hormone pulses

Related goals

Protocols

ProtocolDoseFrequency
Anti-Aging/Wellness100mcg2x daily (morning and bedtime)
Body Composition100-150mcg3x daily (morning, post-workout, bedtime)
Maximum GH Release200mcg2-3x daily with GHRP
Sleep Enhancement100-200mcgOnce at bedtime

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What to expect

Week 2-4

Increased recovery from workouts, reduced soreness, better pumps

Week 4-8

Noticeable improvements in skin quality, minor body composition changes

Week 8-12

More significant lean mass gains, fat loss, improved joint comfort

Week 12+

Continued gradual improvements in body composition and well-being

What to know

  • Generally well-tolerated with minimal side effects at recommended doses
  • May cause temporary facial flushing or warmth for 5-10 minutes post-injection
  • Monitor blood glucose if diabetic; growth hormone can affect insulin sensitivity
  • Not recommended for those with active cancer due to growth-promoting effects
  • Avoid if you have diabetic retinopathy or severe kidney disease

Key research

Teichman SL et al. · Journal of Clinical Endocrinology and Metabolism · 2006
Ionescu M et al. · Journal of Clinical Endocrinology and Metabolism · 2006
Sackmann-Sala L et al. · Growth Hormone & IGF Research · 2009